Physician profile
Benjamin Jones
NPI 1558725762
$2,074.42
in general payments reported to CMS, 2019-2025
35 companies · $514 in 2025
The $514 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $150 · 2022: $54.20 · 2023: $457 · 2024: $737 · 2025: $514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,659 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,658.67 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $300.79 | 2023-2025 | |
| Abbott Laboratories | $290.94 | 2023-2025 | Freestyle Libre 3 |
| Pfizer INC. | $166.70 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $117.54 | 2019-2024 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $82.44 | 2022-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Currax Pharmaceuticals LLC | $80.25 | 2023 | Nexletol, Contrave, Nexlizet |
| Cleerly, INC. | $75.61 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Bayer Healthcare Pharmaceuticals INC. | $75.38 | 2023-2025 | |
| Verity Pharmaceuticals INC. | $71.61 | 2024 | Tlando |
| Inspire Medical Systems, INC. | $64.13 | 2024-2025 | Inspire |
| Lilly USA, LLC | $60.75 | 2020-2025 | Mounjaro, Jardiance |
| Janssen Pharmaceuticals, INC | $60.06 | 2019 | |
| Novo Nordisk INC | $51.50 | 2024 | Wegovy, Ozempic, Rybelsus |
| Ibsa Pharma INC. | $51.01 | 2024-2025 | Tirosint, Licart, Flector |
| Axsome Therapeutics, INC. | $45.66 | 2024 | Auvelity |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $40.67 | 2024 | Aplenzin, Wellbutrin |
| Otsuka America Pharmaceutical, INC. | $38.31 | 2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $34.52 | 2020 | |
| Amgen INC. | $32.69 | 2022-2024 | Evenity, Prolia |
| Kowa Pharmaceuticals America, INC. | $30.61 | 2023-2025 | Livalo, Seglentis, Zoryve |
| Medtronic, INC. | $27.97 | 2023 | Intellis Adaptivestim |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.29 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.91 | 2025 | Jardiance |
| Hologic Sales and Service, LLC | $23.16 | 2025 | Aptima |
| Sanofi-Aventis U.S. LLC | $21.84 | 2025 | |
| Eisai INC. | $21.13 | 2020 | |
| Tolmar, INC. | $21.01 | 2025 | Jatenzo |
| Neuronetics, INC. | $20.46 | 2020 | |
| Astellas Pharma US INC | $20.35 | 2024 | Veozah |
| Vbi Vaccine (Delaware) INC. | $19.56 | 2022 | |
| Merck Sharp & Dohme LLC | $18.32 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $16.81 | 2019 | |
| Sanofi Pasteur INC. | $16.63 | 2020 | |
| Dexcom, INC. | $13.47 | 2023 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $13.34 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.